Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0N68L)

Drug Name

8-(3-Nitro-phenyl)-6-pyridin-4-ylmethyl-quinoline Drug Info

Synonyms

8-(3-nitrophenyl)-6-(pyridin-4-ylmethyl)quinoline; 159925-31-2; RS-14203; CHEMBL127944; 8-(3-Nitro-phenyl)-6-pyridin-4-ylmethyl-quinoline; 8-(3-nitrophenyl)-6-(4-pyridinylmethyl)Quinoline; ZINC6165; SCHEMBL3698956; DTXSID20431317; XRSKAWJXBDACRF-UHFFFAOYSA-N; 3g58; 3g45; BDBM50092632; AKOS022171718; 4CA-1115; KB-74213; DA-09714; AJ-08271; AX8257760; FT-0733089

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 9819356
CAS Number: CAS 159925-31-2
TTD Drug ID: DM0N68L

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Phosphodiesterase 4A (PDE4A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dyphylline	DM8DZC1	Acute bronchial asthma	CA23	Approved	[2]
Enprofylline	DMFYZKN	Asthma	CA23	Approved	[3]
DENBUFYLLINE	DM2R15Q	Cognitive impairment	6D71	Phase 3	[4]
SOTB07	DMIG4OX	Asthma	CA23	Phase 3	[5]
Tofisopam	DMTGNWU	Hyperuricaemia	5C55.Y	Phase 2	[6]
AN-2898	DMDK7CL	Atopic dermatitis	EA80	Phase 2	[7]
GPD-1116	DMOQ7YI	Asthma	CA23	Phase 2	[8]
TA-7906	DMZTAJL	Atopic dermatitis	EA80	Phase 2	[9]
HT-0712	DM2WP8F	Cognitive impairment	6D71	Phase 2	[5]
TOFIMILAST	DMLCUAS	Chronic obstructive pulmonary disease	CA22	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 4A (PDE4A)	TTZ97H5	PDE4A_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl... J Med Chem. 2000 Oct 19;43(21):3820-3.
2	Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
3	Effects of enprofylline, a new xanthine derivate, on human pregnant myometrium. Am J Obstet Gynecol. 1987 Apr;156(4):958-62.
4	Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5.
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
6	The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
7	An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46.
8	Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204.
9	Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6.
10	GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther. 2011 Apr;337(1):145-54.